I really hope someone at RVX is paying attention to the huge opportunity in dealing with the long term effects of prior covid infection. To me given the potential for Apabetalone to repair tissue damaged by covid could potentially set Apabetalone apart from much of the competition. The safety profile with long term use is probably a good leg up for investigation in this vein. The attached articles outline some of the increased long term risks. The fact that there are potentially 10's of millions of prospective patients is hopefully not being overlooked at RVX.

https://www.medicalnewstoday.com/articles/covid-19-survivors-have-an-increased-risk-of-death-12-months-post-infection